Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations

N Engl J Med. 2020 Nov 5;383(19):e107. doi: 10.1056/NEJMp2031373. Epub 2020 Oct 16.

Authors

Philip R Krause¹, Marion F Gruber¹

Affiliation

¹ From the Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD.

PMID: 33064383
DOI: 10.1056/NEJMp2031373

No abstract available

MeSH terms

COVID-19 / prevention & control*
COVID-19 Vaccines* / adverse effects
COVID-19 Vaccines* / immunology
Clinical Trials as Topic / standards
Drug Approval*
Follow-Up Studies
Humans
Pandemics / prevention & control*
United States
United States Food and Drug Administration

Substances

COVID-19 Vaccines